CMIC delivers highly accurate, timely results in days!


• Company of the Year - Awarded by Pharma Tech Outlook Magazine
• 50 Leading Company of the Year 2018 - Silicon Review
• The 10 Best Biotech & Pharma Companies to Keep an Eye On in 2019 - Mirror Review

Learn More
Quality small and large molecule bioanalysis for drug development



Leveraging 30 Years of Experience

Learn More
CMIC delivers highly accurate, timely results in days!


Delivering highly accurate, timely results in days!

Learn More
Purpose Built Bioanalytical Facility and World Class Technology


Purpose Built Facility and World Class Technology

View More

Performing bioanalysis with uncompromising precision

Pharmaceutical Value Creator

CMIC is a bioanalytical Contract Research Organization (CRO) offering:

Small Molecule

Small molecule bioanalysis is a well established science, but not all small molecule studies are straight forward – CMIC is a partner that can handle any situation.

More Info

Large Molecules

Large molecule bioanalysis, immunogenicity and PK testing with higher quality data, with more rapid turnaround and fewer surprises.

More Info


Exploratory biomarker, validation and sample analysis in any matrix or quantity. We make sure biomarker results are accurate and reliable.

More Info


Has supported hundreds of studies for oligonucleotide-based drugs, including: qualification, full method validation and GLP sample analysis.

More Info

Experience, Quality and Results

CMIC is a global Contract Research OrganizationPurpose built in 2010, CMIC’s contract bioanalytical and biomarker laboratory is located just 25 minutes West of Chicago O’Hare International and is one of four global contract laboratories in the CMIC Holdings group. The early growth of CMIC is closely related to the history of CROs in Japan. Founded in 1992, CMIC became the first company to provide CRC/SMO (Site Management Organization) services that are essential for conducting clinical trials in Japan today. Today, CMIC employs more than 6,000 employees worldwide with nearly $600M in sales revenue reported in 2017. CMIC has grown organically, first in Asia Pacific countries and more recently in the United States. CMIC Group acquired a CDMO (Contract Development Manufacturing Organization) in Cranbury, NJ and from JCL Bioassay, the bioanalytical test facility in Hoffman Estates, IL, (CMIC, Inc.). With over 30 years of experience, we aspire to be the top provider of bioanalytical and biomarker services in the world by excellence in communication and customer service, unquestionable data quality and rapid turnaround times. To support growing demand, our laboratory in Hoffman Estates completed construction of an additional 5,000 sq. ft. of dedicated laboratory space, bringing our current footprint to 26,000 sq. ft. on over 5 acres of buildable land. CMIC now houses 17 LC-MS/MS instruments, bringing the CMIC global count to 47 LC-MS/MS instruments. The addition provides us with additional testing capabilities and sample storage space to support 50 freezers. We are eager to let you put our aspirations to the test and welcome the opportunity to discuss your next project.

View the CMIC Main Site Here

"Our vision is to be recognized as a leader in bioanalytical services that clients can trust to deliver high quality data, rapid turnaround, and unparalleled customer service while making every project a success."

Mike Suga
President and CEO

Kunio Momiyama, President and CEO CMIC